Why the study?
Long-term doxorubicin injections lead to severe cardiotoxicity, and phytochemicals targeting the NLRP3 inflammasome represent a potential therapeutic intervention.
Do phytochemicals targeting the NLRP3 inflammasome mitigate doxorubicin-induced cardiotoxicity?
Do phytochemicals targeting the NLRP3 inflammasome mitigate doxorubicin-induced cardiotoxicity?
This review highlights the potential of phytochemicals as a cost-effective therapeutic strategy to mitigate doxorubicin-induced cardiotoxicity via modulation of the NLRP3 inflammasome.
Should not yet change practice for DOX cardioprotection; leaves open human efficacy of phytochemical NLRP3 inhibitors.
Doxorubicin (DOX) has received widespread attention as a broad-spectrum antitumor drug. However, it has been a recognized challenge that long-term DOX injections can lead to severe cardiotoxicity. There are numerous interventions to DOX-induced cardiotoxicity, and the most cost-effective is phytochemicals. It has been reported that phytochemicals have complex and diverse biological properties, facilitating the mitigation of DOX-induced cardiotoxicity. DOX-induced cardiotoxicity has numerous pathological mechanisms, and the nod-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome-mediated cardiomyocyte pyroptosis is one of them. This review initially presents an overview of the pathological mechanisms that underlie cardiotoxicity induced by DOX. Subsequently, we present a comprehensive elucidation of the structure and activation of the NLRP3 inflammasome. Finally, we provide a detailed summary of phytochemicals that can mitigate DOX-induced cardiotoxicity by influencing the expression of the NLRP3 inflammasome in cardiomyocytes.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: